De novo post-diagnosis aspirin use and mortality in women with stage I-III breast cancer

Cancer Epidemiology Biomarkers and Prevention

Volumn 24, Issue 6, 2015, Pages 898-904

  Barron, Thomas I ^a,b   Murphy, Laura M ^a   Brown, Chris ^c   Bennett, Kathleen ^a   Visvanathan, Kala ^b,d   Sharp, Linda ^c  

^a TRINITY COLLEGE DUBLIN   (Ireland)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^c NATIONAL CANCER REGISTRY IRELAND   (Ireland)

^d JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ESTROGEN; NONSTEROID ANTIINFLAMMATORY AGENT; PROGESTERONE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERBB2 PROTEIN, HUMAN; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; PROSTAGLANDIN SYNTHASE INHIBITOR; TUMOR MARKER;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER DIAGNOSIS; CANCER MORTALITY; CANCER REGISTRY; CANCER STAGING; CANCER SURVIVAL; COMORBIDITY; DIABETES MELLITUS; DISEASE ASSOCIATION; DRUG EXPOSURE; DRUG USE; ESTROGEN BLOOD LEVEL; FEMALE; FOLLOW UP; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; PRESCRIPTION; PRIORITY JOURNAL; PROGESTERONE BLOOD LEVEL; RISK ASSESSMENT; TREATMENT DURATION; TUMOR VOLUME; BREAST NEOPLASMS; CANCER GRADING; COHORT ANALYSIS; ENZYME IMMUNOASSAY; IRELAND; METABOLISM; MIDDLE AGED; MORTALITY; PROGNOSIS; SURVIVAL RATE; TUMOR INVASION; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ASPIRIN; BIOMARKERS, TUMOR; BREAST NEOPLASMS; COHORT STUDIES; CYCLOOXYGENASE INHIBITORS; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOENZYME TECHNIQUES; IRELAND; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PROGNOSIS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; SURVIVAL RATE;

EID: 84941764176     PISSN: 10559965     EISSN: 15387755     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-14-1415     Document Type: Article

References (30)

1. Rothwell PM, Price JF, Fowkes FGR, Zanchetti A, Roncaglioni MC, Tognoni G, et al. Short-term effects of daily aspirin on cancer incidence, mortality, and non-vascular death: analysis of the time course of risks and benefits in 51 randomised controlled trials. Lancet 2012;379:1602-12.
2. Rothwell PM, Wilson M, Price JF, Belch JFF, Meade TW, Mehta Z. Effect of daily aspirin on risk of cancer metastasis: a study of incident cancers during randomised controlled trials. Lancet 2012;379:1591-601.
3. Chia WK, Ali R, Toh HC. Aspirin as adjuvant therapy for colorectal cancer-reinterpreting paradigms. Nat Rev Clin Oncol 2012;9:561-70.
4. Zhang X, Smith-Warner SA, Collins LC, Rosner B, Willett WC, Hankinson SE. Use of aspirin, other nonsteroidal anti-inflammatory drugs, and acetaminophen and postmenopausal breast cancer incidence. J Clin Oncol 2012;30:3468-77.
5. Holmes MD, Chen WY, Li L, Hertzmark E, Spiegelman D, Hankinson SE. Aspirin intake and survival after breast cancer. J Clin Oncol 2010;28: 1467-72.
6. Fraser DM, Sullivan FM, Thompson AM, McCowan C. Aspirin use and survival after the diagnosis of breast cancer: a population-based cohort study. Br J Cancer 2014;111:623-7.
7. Blair CK, Sweeney C, Anderson KE, Folsom AR. NSAID use and survival after breast cancer diagnosis in post-menopausal women. Breast Cancer Res Treat 2007;101:191-7.
8. Wernli KJ, Hampton JM, Trentham-Dietz A, Newcomb PA. Use of antidepressants and NSAIDs in relation to mortality in long-term breast cancer survivors. Pharmacoepidemiol Drug Saf 2011;20:131-7.
9. Holmes MD, Olsson H, Pawitan Y, Holm J, Lundholm C, Andersson TM-L, et al. Aspirin intake and breast cancer survival-a nation-wide study using prospectively recorded data in Sweden. BMC Cancer 2014;14:391.
10. Li Y, Brasky TM, Nie J, Ambrosone CB, McCann SE, Shields PG, et al. Use of nonsteroidal anti-inflammatory drugs and survival following breast cancer diagnosis. Cancer Epidemiol Biomarkers Prev 2012;21:239-42.
11. Kwan ML, Habel LA, Slattery ML, Caan B. NSAIDs and breast cancer recurrence in a prospective cohort study. Cancer Causes Control 2007;18: 613-20.
12. Murray LJ, Cooper JA, Hughes CM, Powe DG, Cardwell CR. Post-diagnostic prescriptions for low-dose aspirin and breast cancer-specific survival: a nested case-control study in a breast cancer cohort from the UK Clinical Practice. Breast Cancer Res 2014;16:R34.
13. Barron TI, Cahir C, Sharp L, Bennett K. A nested case-control study of adjuvant hormonal therapy persistence and compliance, and early breast cancer recurrence in women with stage I-III breast cancer. Br J Cancer 2013;109:1513-21.
14. NCRI.DataQuality and Completeness at the Irish NationalCancer Registry [Internet]. 2012 [cited 2013 Nov 23]. Available from: http://www.ncri.ie/pubs/pubfiles/CompletenessQuality.pdf
15. Bastiaannet E, Sampieri K, Dekkers OM, de Craen AJM, van Herk-Sukel MPP, Lemmens V, et al. Use of aspirin postdiagnosis improves survival for colon cancer patients. Br J Cancer 2012;106:1564-70.
16. Greene FL, Page DL, Fleming ID, Fritz A, Balch CM, Haller DG, et al. AJCC Cancer Staging Manual. 6th ed. New York: Springer; 2002.
17. Hillner BE, Penberthy L, Desch CE, McDonald MK, Smith TJ, Retchin SM. Variation in staging and treatment of local and regional breast cancer in the elderly. Breast Cancer Res Treat 1996;40:75-86.
18. ATC classification index with DDDs, 2011. Oslo: WHO Collaborating Centre for Drug Statistics Methodology; 2010.
19. Howlader N, Ries LAG, Mariotto AB, Reichman ME, Ruhl J, Cronin KA. Improved estimates of cancer-specific survival rates from population-based data. J Natl Cancer Inst 2010;102:1584-98.
20. Schneeweiss S, Seeger JD, Maclure M, Wang PS, Avorn J, Glynn RJ. Performance of comorbidity scores to control for confounding in epidemiologic studies using claims data. Am J Epidemiol 2001;154: 854-64.
21. Tevaarwerk AJ, Gray RJ, Schneider BP, Smith ML, Wagner LI, Fetting JH, et al. Survival in patients with metastatic recurrent breast cancer after adjuvant chemotherapy: little evidence of improvement over the past 30 years. Cancer 2013;119:1140-8.
22. Ristimäki A, Sivula A, Lundin J, Lundin M, Salminen T, Haglund C, et al. Prognostic significance of elevated cyclooxygenase-2 expression in breast cancer. Cancer Res 2002;62:632-5.
23. Anderson JR, Cain KC, Gelber RD. Analysis of survival by tumor response. J Clin Oncol 1983;1:710-9.
24. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996;348:1329-39.
25. Waeber B, Leonetti G, Kolloch R, McInnes GT. Compliance with aspirin or placebo in theHypertension Optimal Treatment (HOT) study. J Hypertens 1999;17:1041-5.
26. GallagherAM, Rietbrock S, Plumb J, van Staa TP. Initiation and persistence of warfarin or aspirin in patients with chronic atrial fibrillation in general practice: do the appropriate patients receive stroke prophylaxis? J Thromb Haemost 2008;6:1500-6.
27. Barron TI, Flahavan EM, Sharp L, Bennett K, Visvanathan K. Recent prediagnostic aspirin use, lymph node involvement, and 5-year mortality in women with stage I-III breast cancer: a nationwide population-based cohort study. Cancer Res 2014;74:4065-77.
28. Sledge GW. Clinical trials of metastasis inhibitors: how will they work? AACR 101st Annual Meeting; 2010 April 17-21; Washington, DC; 2010.
29. Chubak J, Boudreau DM, Wirtz HS, McKnight B, Weiss NS. Threats to validity of nonrandomized studies of postdiagnosis exposures on cancer recurrence and survival. J Natl Cancer Inst 2013;105:1456-62.
30. Ring A, Langley RE, Cafferty FH, Gupta S, Wilson RH, Kynaston HG, et al. Abstract OT2-4-01: add-aspirin trial: a phase III double-blind placebo-controlled randomized trial assessing the addition of aspirin after standard primary therapy in breast cancer and other early stage common solid tumours (CRUK/12/033). Cancer Res 2013;73: OT2-4-01.